Ksenia Sukhova

Sep 24, 2024 | nature.com | Thomas Peacock |Ksenia Sukhova |James O. Lloyd-Smith |Anice C. Lowen

AbstractInfluenza A viruses have caused more documented global pandemics in human history than any other pathogen1,2. High pathogenicity avian influenza viruses belonging to the H5N1 subtype are a leading pandemic risk.

Oct 10, 2023 | nature.com | Daniel H. Goldhill |Carol M. Sheppard |Ksenia Sukhova |Jonathan Brown |Ciara Y. Campbell |Salik Nazki | +6 more

AbstractChickens genetically resistant to avian influenza could prevent future outbreaks. In chickens, influenza A virus (IAV) relies on host protein ANP32A. Here we use CRISPR/Cas9 to generate homozygous gene edited (GE) chickens containing two ANP32A amino acid substitutions that prevent viral polymerase interaction. After IAV challenge, 9/10 edited chickens remain uninfected. Challenge with a higher dose, however, led to breakthrough infections.

Oct 10, 2023 | nature.com | Carol M. Sheppard |Daniel H. Goldhill |Olivia Platt |Ksenia Sukhova |Thomas Peacock |Ervin Fodor

AbstractHuman ANP32A and ANP32B are essential but redundant host factors for influenza virus genome replication. While most influenza viruses cannot replicate in edited human cells lacking both ANP32A and ANP32B, some strains exhibit limited growth. Here, we experimentally evolve such an influenza A virus in these edited cells and unexpectedly, after 2 passages, we observe robust viral growth.

Aug 3, 2023 | journals.plos.org | Ksenia Sukhova |Maya Moshe |Paul Kellam |Ruthiran Kugathasan |PLOS Pathogens

DMS reveals most polyclonal vaccine sera select for mutations at one or two antigenic sites in spike RBDHaving validated the platform’s ability to identify mAb escape mutants, we next screened the library for escape from polyclonal sera. Blood was collected from 8 healthy adults between 2–4 weeks after their 2nd BNT162b2 vaccine dose (S1 Table).

Mar 16, 2023 | biorxiv.org | Jonathan Brown |Thomas P. Peacock |Clare P McCormack |Ksenia Sukhova

Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.